LDV

Item no.	HY-P2267-5mg
Manufacturer	MedChem Express
CASRN	1155866-55-9
Amount	5 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.27
Citations	[1]Ben H Njus, et al. Conformational mAb as a tool for integrin ligand discovery. Assay Drug Dev Technol. 2009 Oct;7(5):507-15.\|[2]Estelle Gérard, et al. LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line. Bioorg Med Chem Lett. 2012 Jan 1;22(1):586-90.
Smiles	NCCCC[C@@H](C(O)=O)NC([C@H](C)NC([C@H](C)NC([C@H]1N(C([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC(CC2=CC=C(NC(NC3=CC=CC=C3C)=O)C=C2)=O)=O)=O)=O)CCC1)=O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Integrin
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Molecular Weight	979.13
Product Description	LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells[1][2].
Manufacturer - Research Area	Others
Solubility	DMSO: ≥ 12.5 mg/mL
Manufacturer - Pathway	Cytoskeleton
Clinical information	Phase 4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P2267-5mg-safety-datasheet.pdf